AR062375A1 - Cristal de epotilona b y composiciones farmaceuticas - Google Patents

Cristal de epotilona b y composiciones farmaceuticas

Info

Publication number
AR062375A1
AR062375A1 ARP070103603A ARP070103603A AR062375A1 AR 062375 A1 AR062375 A1 AR 062375A1 AR P070103603 A ARP070103603 A AR P070103603A AR P070103603 A ARP070103603 A AR P070103603A AR 062375 A1 AR062375 A1 AR 062375A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
crystal
epotilone
epothilone
ray diffraction
Prior art date
Application number
ARP070103603A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR062375A1 publication Critical patent/AR062375A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP070103603A 2006-08-16 2007-08-14 Cristal de epotilona b y composiciones farmaceuticas AR062375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119043 2006-08-16

Publications (1)

Publication Number Publication Date
AR062375A1 true AR062375A1 (es) 2008-11-05

Family

ID=37685905

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103603A AR062375A1 (es) 2006-08-16 2007-08-14 Cristal de epotilona b y composiciones farmaceuticas

Country Status (22)

Country Link
US (1) US8178566B2 (enExample)
EP (1) EP2064216A2 (enExample)
JP (1) JP2010500387A (enExample)
KR (1) KR20090038902A (enExample)
CN (1) CN101506217B (enExample)
AR (1) AR062375A1 (enExample)
AU (1) AU2007286454A1 (enExample)
BR (1) BRPI0715963A2 (enExample)
CA (1) CA2658475A1 (enExample)
CL (1) CL2007002362A1 (enExample)
IL (1) IL196558A0 (enExample)
MA (1) MA30656B1 (enExample)
MX (1) MX2009001635A (enExample)
MY (1) MY148355A (enExample)
NO (1) NO20091081L (enExample)
NZ (1) NZ574194A (enExample)
PE (1) PE20081317A1 (enExample)
RU (1) RU2009109352A (enExample)
TN (1) TN2009000044A1 (enExample)
TW (1) TW200815455A (enExample)
WO (1) WO2008019820A2 (enExample)
ZA (1) ZA200900227B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052974B1 (en) 1998-02-05 2009-05-20 Novartis AG Pharmaceutical formulation containing epothilone
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
BRPI0314133A8 (pt) * 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona

Also Published As

Publication number Publication date
CL2007002362A1 (es) 2008-08-08
AU2007286454A1 (en) 2008-02-21
MY148355A (en) 2013-03-29
CN101506217B (zh) 2012-09-05
WO2008019820A3 (en) 2008-04-17
IL196558A0 (en) 2009-11-18
TN2009000044A1 (en) 2010-08-19
US8178566B2 (en) 2012-05-15
WO2008019820A2 (en) 2008-02-21
NO20091081L (no) 2009-03-16
BRPI0715963A2 (pt) 2013-08-06
KR20090038902A (ko) 2009-04-21
JP2010500387A (ja) 2010-01-07
CN101506217A (zh) 2009-08-12
NZ574194A (en) 2011-12-22
PE20081317A1 (es) 2008-10-28
TW200815455A (en) 2008-04-01
MA30656B1 (fr) 2009-08-03
CA2658475A1 (en) 2008-02-21
RU2009109352A (ru) 2010-09-27
US20100160393A1 (en) 2010-06-24
EP2064216A2 (en) 2009-06-03
ZA200900227B (en) 2009-12-30
MX2009001635A (es) 2009-02-23

Similar Documents

Publication Publication Date Title
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
PA8809601A1 (es) Combinación anti-retroviral
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
UY32252A (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
AR052925A1 (es) Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
UY29266A1 (es) Compuestos de piridazinona
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
AR109263A2 (es) Composición que comprende moxidectina
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
ES2531516T3 (es) Uso de escina
AR053803A1 (es) Uso de acido pinolenico
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
AR111471A2 (es) Composición de combinación sinérgica
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal